Results 31 to 40 of about 28,144 (206)

Apixaban for the prevention of thromboembolism in adults after elective hip or knee replacement surgery, and in symptomatic venous thromboembolism [PDF]

, 2012
The anticoagulant effect of apixaban is due to direct inhibition of FXa in the coagulation cascade. The main advantages apixaban has over the current anti-coagulant drugs is that it is active after oral administration, and its coagulation effect does not
Doggrell, Sheila
core   +1 more source

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation

Journal of Arrhythmia, 2017
Background: The periprocedural protocol for atrial fibrillation (AF) ablation commonly includes anticoagulation therapy. Apixaban, a direct oral anticoagulant, is currently approved for clinical use; however, little is known about the effects of residual
Yutaro Mukai, Kyoichi Wada, Koji Miyamoto, Kazuki Nakagita, Mai Fujimoto, Kouichi Hosomi, Takeshi Kuwahara, Mitsutaka Takada, Kengo Kusano, Akira Oita   +9 more
doaj   +1 more source

A Dangerous and Unrecognized Interaction of Apixaban [PDF]

, 2021
Direct oral anticoagulants (DOACs) drug-to-drug interactions are underrecognized by clinicians. Apixaban has cytochrome 450 (CYP) mediated metabolism (primarily by CYP3A4).
Govindu, Rukma R, Ammar, Hussam
core   +1 more source

Impact of ileostomy creation on apixaban plasma concentrations: a retrospective case-series

Annals of Saudi Medicine
BACKGROUND: Apixaban is a direct-acting oral anticoagulant indicated for stroke and systemic embolism prevention in atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE).
Hakeam A. Hakeam, Sandra McGrath, Ghader Alrebeh, Abdullah F. Alrebdi   +3 more
doaj   +1 more source

Carbamazepine Induction Impacting Apixaban Concentrations: A Case ReportNovel Teaching Points

CJC Open, 2020
Avoidance of apixaban with carbamazepine (CBZ) is recommended owing to an anticipated reduction in apixaban concentration, although this drug interaction is poorly described. We report a case wherein apixaban concentration was measured before and 2 weeks
Tammy J. Bungard, BSP, PharmD, R. Neil Roberts, MD   +1 more
doaj   +1 more source

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

CPT: Pharmacometrics & Systems Pharmacology, 2023
Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant therapy.
Samira J. Merali, Wonkyung Byon, Yogesh T. Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy   +8 more
doaj   +1 more source

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy

Hitit Medical Journal, 2020
An 80-year-old female was admitted to the hospital, presenting a pulsatile and painless mass on the right temporal site occurred one month ago following a blunt head trauma.
Sertan Özyalçın, Adem İlkay Diken, Adnan Yalçınkaya, Ufuk Türkmen   +3 more
doaj  

Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels

Research and Practice in Thrombosis and Haemostasis, 2021
Introduction Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer‐associated thrombosis (CAT) as reported in the ADAM‐VTE and Caravaggio studies, which ...
Verónica Bravo Villa, Job Romero, Eunice Rojas‐Zaldivar, Martha Cervantes, María del Rosario Villa‐Márquez, Patricia Baz, Gabriela Cesarman‐Maus   +6 more
doaj   +1 more source

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration

Frontiers in Veterinary Science, 2018
Horses with inflammatory and infectious disorders are often treated with injectable heparin anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral acting anticoagulants (DOAC) appear as effective as heparin, while ...
Priscila B. S. Serpa, Marjory B. Brooks, Thomas Divers, Sally Ness, Ingvild Birschmann, Mark G. Papich, Tracy Stokol   +6 more
doaj   +1 more source